Chester, John - Cardiff University

个人简介

John is the Director of the Wales Cancer Research Centre and an academic clinician. His academic roles in the College of Biomedical and Life Sciences at Cardiff University include Professor of Oncology in the School of Medicine, and Lead for the College’s Cancer Research Theme. His clinical work is as Honorary Consultant in Medical Oncology at the Velindre Cancer Centre in Cardiff. He qualified in medicine from St. Mary’s Hospital Medical School (Imperial College, London) in 1993, having previously completed a first degree in biochemistry in Oxford and a PhD in molecular biology at the Beatson Institute for Cancer Research in Glasgow. He completed specialist training in 1996 and remained in Yorkshire as Clinical Senior Lecturer and Honorary Consultant in Medical Oncology at St. James’s University Hospital, Leeds between 2002 and 2011. John’s clinical practice has predominantly been in bladder cancer, germ cell tumours and head/neck cancers, and he has specialist clinical research interests in trials for bladder and head/neck cancers, and in stratified medicine. His laboratory research interests include virus-mediated gene therapy and molecular biomarkers of response to cancer therapy. Amongst his various other roles are: Lead for the Cardiff Experimental Cancer Medicine Centre (ECMC); strategic lead for the Velindre Cancer Centre Phase I trials unit; and Deputy Director of the Wales Cancer Bank. He serves on Cancer Research UK’s New Agents Committee, the Advisory Board for its Centre for Drug Development and its Clinical Career Committee. He also sits on the Management Board of Welsh National Research Network for Life Sciences.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Hulin-Curtis, S.et al. 2016. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Therapy 23(7), pp. 229-234. (10.1038/cgt.2016.22) pdf Uusi-Kerttula, H.et al. 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7(19), pp. 27926-27937. (10.18632/oncotarget.8545) pdf Powles, T.et al. 2016. A phase II/III, double-blind, randomised trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients. Journal of Clinical Oncology , article number: 663468. Baird, R.et al. 2016. An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. ecancermedicalscience 10, article number: 608. (10.3332/ecancer.2016.608) pdf Hulin-Curtis, S.et al. 2015. Evaluation of CD46 utilising adenoviral vectors for clinical ovarian cancer applications [Abstract]. Human Gene Therapy 26(9), pp. A33-A34. Uusi-Kerttula, H.et al. 2015. Development of an Ad5 vector pseudotyped with Ad48 knob protein and targeted to alpha v beta 6 integrin efficiently targets tumour cells and evades pre-existing immunity in clinical ascites [Abstract]. Human Gene Therapy 26(9), pp. A33-A33. (10.1089/hum.2015.29005.abstracts) Uusi-Kerttula, H.et al. 2015. Modulation of Ad5 fibre knob as a means of circumventing pre-existing immunity in clinical ovarian ascites [Abstract]. Human Gene Therapy 26(9), pp. A23-A23. (10.1089/hum.2015.29005.abstracts.) Collins, J.et al. 2015. Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol. BMC Cancer 15, article number: 544. (10.1186/s12885-015-1565-6) pdf Jackson, S. E. and Chester, J. D. 2015. Personalised cancer medicine. International Journal of Cancer 137(2), pp. 262-266. (10.1002/ijc.28940)